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Abstract: The growth factor bone morphogenetic protein 2 (BMP2) plays an important role in bone
development and repair. Despite the positive effects of BMP2 in fracture healing, its use is associated
with negative side effects and poor cost effectiveness, partly due to the large amounts of BMP2
applied. Therefore, reduction of BMP2 amounts while maintaining efficacy is of clinical importance.
As nitric oxide (NO) signaling plays a role in bone fracture healing and an association with the
BMP2 pathway has been indicated, this study aimed to investigate the relationship of BMP2 and NO
pathways and whether NO can enhance BMP2-induced signaling and osteogenic abilities in vitro.
To achieve this, the stable BMP reporter cell line C2C12BRELuc was used to quantify BMP signaling,
and alkaline phosphatase (ALP) activity and gene expression were used to quantify osteogenic
potency. C2C12BRELuc cells were treated with recombinant BMP2 in combination with NO donors
and substrate (Deta NONOate, SNAP & L-Arginine), NOS inhibitor (LNAME), soluble guanylyl
cyclase (sGC) inhibitor (LY83583) and activator (YC-1), BMP type-I receptor inhibitor (LDN-193189),
or protein kinase A (PKA) inhibitor (H89). It was found that the NOS enzyme, direct NO application,
and sGC enhanced BMP2 signaling and improved BMP2 induced osteogenic activity. The application
of a PKA inhibitor demonstrated that BMP2 signaling is enhanced by the NO pathway via PKA,
underlining the capability of BMP2 in activating the NO pathway. Collectively, this study proves the
ability of the NO pathway to enhance BMP2 signaling.
Keywords: C2C12; BMP2; nitric oxide; signaling; crosstalk
1. Introduction
Bone morphogenetic proteins (BMPs) provide approximately 20 members to the transforming
growth factor beta (TGFβ) superfamily. BMPs are archetypal growth factors capable of inducing
diverse cellular responses such as proliferation, survival, apoptosis, differentiation, and migration,
and play an important role in the development and homeostasis of bone [1]. BMPs act not only in
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the skeleton, but also have roles in other tissue types, for example, in tendons [2], nerve synapses [3],
and endothelial cells [4].
BMPs have become clinically relevant [5], particularly in the orthopedic discipline [6–8],
where BMP2 is licensed for the treatment of open tibia fractures [9]. Clinical trials highlight the
ability of BMP2 to improve health outcomes of patients with open tibia shaft fracture by significantly
reducing healing times, complications, infections, further operations, and hardware failures compared
to the standard care group [10,11]. A clinical trial of rhBMP2 in the treatment of open tibia fractures
did not find a clear improvement in fracture healing. However, rhBMP2 reduced the failure rates of
surgical interventions, therefore reducing the need for further clinical interventions [8].
With current clinical applications of BMP2 being 1000 times greater than physiological levels, it is
not surprising that negative effects, such as poor bone structure and excess inflammation, have become
apparent [12–14]. Clinical trials have indicated issues with the effectiveness of BMP2 and negative
effects, such as increased signs of edema and deep venous thrombosis [15] or prolonged inflammatory
response (wound drainage) [16]. The Orthopedic Research Society Forum [14] stated that the excessive
clinical doses of rhBMP2 (compared to normal physiological amounts) could be the underlining
issue in negative outcomes and that there is a need to refine and reduce rhBMP2 application in the
clinic. One possibility is to optimize BMP2 treatment through the enhancement of BMP-signaling by
modulating this pathway.
BMP2 binds dimeric BMP receptor type 1 (BMPR1a, BMPR1b) and type 2 (BMPR2,
ActR2A, ActR2B), thus forming hetero-tetrameric receptor complex [17,18]. The affinities between
BMP2 and the various receptors differ, generating complexity and redundancy in BMP signaling [19].
The long C-terminal cytoplasmic tail of the type 2 receptor BMPR2 contains valuable binding sites
for adapter proteins [20–22]. This extra binding allows for interactions with additional proteins that
lead to modulations of signaling processes such as CD117, tribbles 3 (Trb-3), protein phosphatase 2
(PP2), protein kinase A (PKA), and cGMP dependent kinase I (cGKI) [23–27].
The NO pathway effector kinase, cGKI, was shown to play a role at many points of BMP signaling.
cGKI associates with and phosphorylates the BMPR2 tail-domain [28]. Once the receptor is activated
by ligand binding, cGKI leaves the receptor to associate with and enhance the action of SMAD
transcription factors [26,29]. In pulmonary arterial endothelial cells, PKA was described as a crucial
link between the NO- and BMP-pathway [27]. Endothelial cells treated with BMP2/4 activate PKA
via BMPR2 which, in turn, mediates phosphorylation of the endothelial NO synthase (eNOS) [27].
Here, we asked whether there is an association between the NO- and BMP2-pathways in the context of
BMP2-mediated osteo-inductive activity. This might have important implications for improvement of
BMP2-based therapeutics.
The NO pathway has been associated with osteo-inductive activities. The application of
a NOS inhibitor (LNAME) to rats following bone fracture led to reduction in bone healing,
which was recovered by direct NO donation [30]. The application of nitrates (e.g., nitroglycerin)
has been shown to reduce osteopenia and osteoporosis in animal models [31–33]. In clinical trials,
nitrate-treated female osteoporotic patients showed an increase in osteogenic markers and bone
density [34–36]. This association between the NO and BMP2 pathway could prove valuable in
improving BMP2-mediated osteogenic activities. For this purpose, the BMP2 sensitivity [37] and
osteogenic features [38–40] of the mouse C2C12 myoblast cell line were exploited to investigate whether
the NO pathway combines and enhances the effects of the BMP2 pathway, and if the BMP2 pathway is
capable of modulating the NO pathway.
2. Materials and Methods
2.1. Cell Culture
The C2C12BRELuc reporter cell line [41] was generated by the Inman group and used in this study.
In this cell line, the luciferase (Luc) reporter is under the control of the BMP response elements (BRE) of
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the Id1 gene. C2C12BRELuc were cultivated in culture medium (Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% heat-inactivated fetal bovine serum (FBS) and antibiotics (100 U/mL
penicillin and 100 µg/mL streptomycin, all from Biochrom AG, Berlin, Germany). C2C12BRELuc cells
were passaged twice per week in a 175 or 225 cm2 cell culture flask. The cultivation media was
supplemented with the antibiotic G418 (0.7 mg/mL) to select for the BREluc-positive C2C12BRELuc
cells in accordance with previous studies [41].
C2C1BRELuc cells were sub-cultivated at a ratio of 2.5–5 × 104 cells per mL of
culture medium. DMEM, antibiotics, FBS, and trypsin (Biochrom AG, Berlin, Germany) were
used in cell cultivation and passaging. To ensure the viability and to calculate
cell number, the metabolic activity of cells was calculated through Presto Blue® assay
(Invitrogen by Life Technologies Co., Carlsbad, CA, USA). BMP2 was purchased from Osteogenetics
(Würzburg, Germany). H89 was purchased from AbCam (Cambridge, UK). Deta NONOate,
SNAP, YC-1, LY83583, LDN-193189, and IBMX were purchased from Cayman Chemical (Ann Arbor,
MI, USA).
2.2. BMP Reporter Assay
The experimental setup utilized 0.1% FCS, as it allows C2C12 cells to respond rapidly to BMP2.
Cells were seeded at a density of 2.5 × 104 cells per well in culture media into 48-well cell culture dishes
overnight. The medium was exchanged to Dulbecco's Modified Eagle Medium (DMEM) without
l-Arginine (GIBCO® by Life Technologies GmbH, Darmstadt, Germany) supplemented with 0.1% FCS
and 1% Pen/Strep for starvation for three hours. Subsequently, medium was changed to the appropriate
stimulation medium for the stated period of time (see Table 1 for experimental setup). The medium
was removed after the stimulation period and the cells were lysed in 100 µL lysis buffer (1:5 Cell
Lysis Reagent diluted in ddH2O; Promega, Mannheim, Germany), frozen at −20 ◦C, and subsequently
thawed at room temperature on a shaker. The cell lysate (20 µL) was then transferred to a 96-well plate
and 50 µL of Luciferase buffer (Promega, Mannheim, Germany) was added by automatic injection using
a luminometer (Mithras LB-940, Berthold Technologies, Bad Wildbad, Germany). Quantification was
determined as relative light units (RLU). For protein normalization, the protein content of lysates was
determined with the Pierce™ Coomassie assay (Thermo Fisher Scientific, Darmstadt, Germany) and
Bovine Serum Album (BSA) as standard. The assay was carried out following manufactures instruction.
Standards were made in PBS (or appropriate experimental buffer) and samples were diluted 1:2 in PBS
and measured in triplicates.
Table 1. Experimental setups for this study.
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2.3. Alkaline Phosphatase Activity (ALP) Assay
C2C12BRELuc cells were seeded at a density of 2 × 104 per well in a 24-well plate and incubated in
DMEM High Glucose (Biochrom AG, Berlin, Germany) supplemented with 10% FCS and 1% Pen/Strep.
Prior to starvation, the cell number was quantified using Presto Blue® Assay. After starvation with 1%
FCS, 1% Pen/Strep in DMEM/Ham’s F-12 (Biochrom AG, Berlin, Germany) for three hours, cells were
stimulated with the same medium for three days (Table 1). Following stimulation, the medium was
aspirated and cells were washed with pre-warmed PBS. ALP activity was analyzed by the addition of
1 mL of ALP buffer (50 mM glycine, 100 mM TRIZMA base, 1 mM MgCl2, pH 10.5) containing 1.3 mg
pNPP (Sigma-Aldrich, Hamburg, Germany) per well. After incubation for one hour at 37 ◦C, 180 µL
medium was transferred to a clear 96-well plate in triplicates and the absorbance was quantified at
405 nm using a spectrophotometer.
2.4. Gene Expression Analysis
For expression analysis of inhibitor of differentiation (Id), 1, 2, and 3, 5 × 105 cells were seeded to
six-well cell culture dishes in culture medium. The next day, cells were starved for three hours in
starving medium. The cells were then stimulated for six hours (Table 1).
Osteogenic differentiation was determined by expression analysis of osteoprotegerin (OPG),
collagen type I alpha 1 chain (Col1a1), and runt-related transcription factor 2 (Runx2). A total of 1.2 × 105 cells
was cultivated in culture medium overnight and starved with DMEM without Arginine (supplemented
with 1% FCS and 1% antibiotics) for three hours. Stimulation was done for six days with a complete
medium change after three days (Table 1).
RNA isolation was carried out using the NucleoSpin® RNA kit (Macherey-Nagel, Düren, Germany)
following the instructions. The RNA was dissolved in 30 µL RNAase Free H2O and RNA concentration
was measured using a spectrophotometer.
Typically, 500 ng RNA was translated into cDNA using qScript cDNA SuperMix (Quantabio,
Beverly, MA, USA) according to the manufacturer’s protocol. The mRNA expression of the genes
of interest was quantified using quantitative real-time polymerase chain reaction (qRT-PCR).
The reaction mixture was composed of 25–50 ng cDNA with 10 µM primers (see Table 2,
TIB-MOLBIOL Syntheselabor GmbH, Berlin, German), nuclease-free H2O, and PerfeCTa SYBR®
Green SuperMix (Quantabio, Beverly, MA, USA). Next, 15 µL of the reaction mixture was transferred
to a white 96-well qRT-PCR plate and LightCycler 480 System (Roche, Mannheim, Germany) was used.
The amplification protocol included 40 cycles with an annealing temperature at 60 ◦C, followed by
a melting curve protocol until 95 ◦C with a ramp rate of 0.11 ◦C/sec. The efficiency was tested
for all primers and the ∆Ct method with efficiency correction was used to calculate the relative
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gene expression to the housekeeping gene hypoxanthine-guanine phosphoribosyl-transferase (HPRT).
HPRT was chosen as a housekeeping gene as it was most constant over the different stimulation
conditions compared to other housekeeping genes such as Actin (NM_009608.3), Eukaryotic Translation
Elongation Factor 1 alpha 2 (NM_010106), Ribosomal protein L13 (NM_016738.5), 18S rRNA (NR_003278.3),
and Glycerinaldehyd-3-phosphat-Dehydrogenase (NM_001289726.1). For exemplary melting curves of
qRT-PCR see Figure S1.
Table 2. Murine primers for quantitative real-time polymerase chain reaction (qRT-PCR).
Gene Accession Number Forward (5′→3′) Reverse (5′→3′)
HPRT NM_000194 TTGCTGACCTGCTGGATTAC AACTTTTATGTCCCCCGTTG
Id1 NM_010495.3 ACGACATGAACGGCTGCTACT GCTCACTTTGCGGTTCTGG
Id2 NM_010496.3 TATCAGCCATTTCACCAGGAG TGTGAAAAGGCAAAGTCTGCT
Id3 NM_008321 AAGGACAAGAGGAGCTTTTGC GCGTTGAGTTCAGGGTAAGTG
OPG NM_002546.3 TGCAGTACGTCAAGCAGGAG CCCATCTGGACATCTTTTGC
Col1a1 NM_000088.3 TGACCTCAAGATGTGCCACT ACCAGACATGCCTCTTGTCC
Runx2 NR_103532 GCCCCCAAACAGTATCTTGA GCCTGAAGTGAGGTTTTAGGC
2.5. NO Quantification
NO quantification protocol was modified from Hinchee-Rodriguez et al. 2013 [42].
C2C12BRELuc cells were seeded at a density of 6 × 104 cells per well of a 24-well plate with
DMEM High Glucose 10% FCS and 1% Pen/Strep and incubated overnight. Following starvation,
cells were loaded for one hour with 5 µM DAF-2 (Biomol GmbH, Hamburg, Germany) in serum-free
PBS. Subsequently, cells were stimulated for two hours in DMEM High Glucose supplemented with
1% FCS and 1% Pen/Strep. Following stimulation, cells were washed twice with warm PBS and
fluorescence was quantified using a spectrophotometer at 485 nm excitation and 538 nm emission.
The direct NO donor DetaNONOate was employed as a positive NO control.
2.6. cGMP ELISA
C2C12BRELuc cells were seeded in six-well plates with 6 × 105 cells per well in culture medium
overnight. Three hours of starvation and one hour of stimulation were carried out in DMEM without
Arginine with 1% FCS. The inhibitor of cGMP degradation IBMX (500 µM) was added during starvation
and stimulation to all samples. Post-stimulation, cells were washed with cold PBS, aspirated, and 500µL
0.1 M HCL was added. After 10 min incubation at room temperature, the plate was stored at −20 ◦C.
Subsequent thawing was followed by scrapping of cells. The lysates were then aliquoted into protein
LoBind tubes (Eppendorf, Hamburg, Germany) and centrifuged at 600× g for 10 min at 4 ◦C.
The cGMP ELISA (NewEast Biosciences, King of Prussia, PA, USA) assay was carried out following
the standard protocol from the manufacturer and absorption was measured at 450 nm for HRP and
570 nm reference using a spectrophotometer. The normalization of samples was carried out using
Coomassie assay.
2.7. SMAD-1 ELISA
C2C12BRELuc cells were seeded with 5 × 104 cells per well in a 24-well plate and incubated in
culture medium overnight. The next day, cells were starved in DMEM without Arginine, supplemented
with 0.1% FCS and 1% antibiotics for three hours. One hour before starving ended and during
stimulation, the BMP type-I receptor inhibitor LDN was supplemented to the inhibitor group.
Stimulation was carried out with the same medium supplemented with BMP2 and Arginine (Table 1)
for 30 min.
Phosphorylated and total SMAD1 were measured with the SMAD1 InstantOne ELISA™ kit,
Invitrogen by Life Technologies Co., Carlsbad, CA, USA. Cells were incubated with Cell Lysis Mix
(1:5 Cell Lysis Reagent diluted in ddH2O, provided in the kit) for 10 min at room temperature and
lysates were transferred to protein LoBind tubes. Samples were stored on ice and ELISA was directly
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carried out after sample taking following manufacturers instruction. Absorption was measured with
a spectrophotometer at 450 nm with reference at 570 nm. Phosphorylated SMAD1 was normalized to
total SMAD1.
2.8. Statistics
All experiments were done in triplicate and repeated at least once (except for the PCR).
The statistical analyses were performed using IBM® SPSS® Statistics version 22. All graphs were
visualized as boxplots. The mild outliers are marked with a circle and extreme outliers are marked with
a star. The nonparametric Kruskal-Wallis test was used to determine if there were statistically significant
differences between all groups. In cases of significances during Kruskal-Wallis tests, a comparison
between two groups was made by Mann-Whitney U test. The significances are given in the figures and
are assigned if p < 0.05 (*), p < 0.01 (**), or p < 0.001 (***).
3. Results
C2C12 is a myoblast precursor cell line, which is responsive to BMPs [37] and possess osteogenic
features [38–40]. The stable transfection of C2C12 cells with a luciferase (Luc) reporter composed of
SMAD-binding BMP response elements (BRE) has provided a valuable tool in the quantification of
BMP activity [41]. In order to investigate the possible NO-BMP crosstalk, Arginine-free DMEM was
used to have better control over the NO pathway.
3.1. BMP2-Mediated Signaling and Osteogenic Activity Can be Enhanced by Arginine Via NOS
3.1.1. Arginine Supports BMP2-Mediated Activity
Arginine, a substrate of the NOS enzyme, was investigated to determine its effect on BMP2
signaling. After 24 h of stimulation, C2C12BRELuc cells showed no increase in reporter activity in
response to supplementation of Arginine alone (Figure 1A). Arginine supplementation in combination
with 1 nM or 5 nM BMP2 demonstrated a significant increase in BMP2-induced BMP reporter activity
(Figure 1B,C). Co-stimulation of the cells with 1 nM BMP2 and Arginine was as effective as stimulation
with 5 nM BMP2 alone. The expression of the immediate BMP2 response genes Id1, Id2, and Id3
was examined following six hours of stimulation with 1 nM BMP2 with or without 1 mM Arginine
(Figure 1D). The stimulation with BMP2 increased expression of the target genes as expected, which was
further stimulated by the application of the NOS substrate Arginine (Figure 1D).
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Figure 1. Bone morphogenetic protein (BMP) reporter activity and BMP target gene expression after
stimulation with the nitric oxide synthase (NOS) substrate Arginine. C2C12BRELuc cells stimulated
for 24 h in Arginine-free Dulbecco's Modified Eagle Medium (DMEM) with (A) 0.1 to 7.5 mM Arginine
alone or in combination with (B) 1 nM BMP2 or (C) 5 nM BMP2. (D) C2C12BRELuc cells were
stimulated for six hours in Arginine-free DMEM with 1 nM BMP2, with or without 1 mM Arginine.
The gene expression of Id1, Id2, and Id3 was investigated. Statistics: Kruskal–Wallis Test followed by
Mann-Whitney U test. Mann-Whitney U test significances between samples were assigned if p < 0.05
(*) or p < 0.01 (**). Stars and circles are outlying values. Number of replications: (A) n = 12; (B) n = 6;
(C) n = 9; (D) n = 3.
3.1.2. Arginine Support of BMP2 Activity is Mediated by NOS
To further demonstrate that the application of Arginine supports BMP2-mediated SMAD signaling
via the NO pathway, the inhibitor of the NOS enzyme (LNAME) was applied to C2C12BRELuc
cells. The application of LNAME (250 µM–10000 µM; high concentration in accordance to [43]) alone
had no effect on the BMP reporter activity (Figure 2A). The Arginine-enhanced BMP2 signaling was
significantly reduced by LNAME (5,000 µM and 10,000 µM) (Figure 2B). ALP activity was utilized
to investigate the osteoinductive effect of BMP2. For this assay, cells were cultured for three days.
The application of LNAME at 10 and 100 µM reduced significantly the BMP2-mediated ALP activity
(Figure 2C). Subsequently, LNAME inhibition of BMP2-mediated ALP activity was recovered by the
direct application of direct NO donor Deta NONOate (Figure 2D).
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Figure 2. BMP reporter and alkaline phosphatase activity (ALP) activity following the inhibition
of NOS enzyme by NOS inhibitor (LNAME): C2C12BRELuc cells were stimulated for 24 h with (A)
250-10,000 µM LNAME or (B) 5 nM BMP2 and 1 mM Arginine in combination with 250-10,000 µM
LNAME. ALP activity was normalized to cell number of cells stimulated for 72 h with 10 nM BMP2 with
(C) NOS inhibitor LNAME (0.01 to 100 µM) and (D) following recovery of 10 µM or 100 µM LNAME
inhibition with the direct NO donor. Statistics: Kruskal–Wallis Test followed by Mann-Whitney U test.
Mann-Whitney U test significances between samples were assigned if p < 0.05 (*) or p < 0.01 (**) or
p < 0.001 (***). Stars and circles are outlying values. Abbreviation: Deta: Deta NONOate. Number of
replications: (A–D) n = 6.
3.2. BMP2-Mediated Signaling and Osteogenesis Can be Enhanced by Direct NO Donor
The NO donors Deta NONOate and SNAP release NO spontaneously at different rates.
Deta NONOate has a half-life of 20 h, whereas SNAP has a half-life of six hours. The use of Deta
NONOate (10–1000 µM) alone or in combination with 1 nM BMP2 for six hours had no significant
effect on BMP reporter activity (Figure 3A,B). Application of SNAP (1–100 µM) alone significantly
increased BMP reporter activity compared to untreated controls (Figure 3C), while co-application of
SNAP (1–100 µM) with 1 nM BMP2 had no significant effect on reporter activity compared to BMP2
alone (Figure 3D).
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significantly increased BMP reporter activity compared to BMP2 alone in a dose-dependent manner 
(Figure 4B). Interestingly, in Arginine-containing media, a lower dose of Deta NONOate (1 and 10 
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Due to the fact that no effect was observed after six hours, the experiment was repeated with
a stimulation period of 24 h. For this 24 h timepoint, Deta NONOate alone (1–100 µM) stimulated
BMP reporter activity (Figure 4A). The combined use of Deta NONOate (1–100 µM) and 1 nM BMP2
significantly increased BMP reporter activity compared to BMP2 alone in a dose-dependent manner
(Figure 4B). Interestingly, in Arginine-containing media, a lower dose of Deta NONOate (1 and 10 µM)
with 1 nM BMP2 had an additional effect on the cells, while a high concentration of Deta NONOate
(100 µM) and 1nM BMP2 was inhibitory (Figure 4C). The combination of SNAP (5–50 µM) with 1 nM
BMP2 had no effect on reporter activity compared to BMP2 alone (Figure 4D).Cells 2019, 8, x 9 of 22 
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The ALP activity of C2C12BRELuc cells was used as an outcome measure of osteogenic 
differentiation. Since Arginine-free media was unable to mediate an increase of ALP activity in 
response to BMP2, cells were cultured in DMEM-HAMs with 1% FCS [44]. Stimulation of cells with 
Deta NONOate (10–100 μM) for 72 h showed no significant difference in ALP activity compared to 
untreated cells except for a reduction of activity by 25 μM Deta NONOate (Figure 5A). The co-
stimulation of cells with different concentrations of BMP2 (4, 10, 20 nM) and Deta NONOate (10–100 
μM) revealed a complex relationship depending on the concentration combinations. Only the low 
Deta NONOate concentration (10 μM) in combination with 10 and 20 nM BMP2 significantly 
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than at 20 nM BMP2. 
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The ALP activity of C2C12BRELuc cells was used as an outcome measure of osteogenic
differentiation. Since Arginine-free media was unable to mediate an increase of ALP activity in
response to BMP2, cells were cultured in DMEM-HAMs with 1% FCS [44]. Stimulation of cells with
Deta NONOate (10–100 µM) for 72 h showed no significant difference in ALP activity compared
to untreated cells except for a reduction of activity by 25 µM Deta NONOate (Figure 5A). The
co-stimulation of cells with different concentrations of BMP2 (4, 10, 20 nM) and Deta NONOate (10–100
µM) revealed a complex relationship depending on the concentration combinations. Only the low Deta
NONOate concentration (10 µM) in combination with 10 and 20 nM BMP2 significantly stimulated
ALP activity (Figure 5B–D). The stimulatory effect was more pronounced at 10 nM BMP2 than at 20
nM BMP2.
The effect of NO donation on BMP mediated osteogenic differentiation was further tested in a
six-day stimulation experiment in Arginine-free DMEM supplemented with BMP2 with and without
Arginine. BMP significantly stimulated the expression of OPG and Runx2 compared to the unstimulated
control, while Col1a1 expression was not affected. Further Arginine supplementation significantly
enhanced the BMP-mediated osteogenic differentiation as determined by Runx2, Col1a1 expression,
without reaching significant differences in OPG expression (Figure 6).Cells 2019, 8, x 10 of 22 
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markers of C2C12 cells, can further be enhanced by a NO onor.
3.3. NO Receptor, sGC, Assists in B P2 Induced Signaling
The NO pathway relies on the NO receptor, soluble guanylyl cyclase (sGC), as part of the signal
transduction pathway. Therefore, understanding the effects of inhibition (LY83583, Figure 7) and
NO-independent activation (YC-1, Figure 7) of this receptor is important to demonstrate the effect
of the NO pathway on supporting BMP2 signaling activity. C2C12BRELuc cells were treated with
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LY83583 and 1 nM BMP2, with and without 100 µM Deta NONOate (Figure 7A). Both concentrations
of LY83583 (10 and 100 µM) significantly reduced BMP2 signaling without a further effect of direct NO
application (Figure 7A). The addition of LY83583 (0.01–0.5 µM) reduced significant the BMP induced
ALP activity (Figure 7B). At the three-day period required for ALP activity, high concentrations of
LY83538 (10–100 µM) resulted in a decrease in cell number, either due to the longer time or change in
media type.
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Figure 7. BMP reporter and ALP activity after inhibition of soluble guanylyl cyclase (sGC):
C2C12BRELuc cell line was stimulated for 24 h in DMEM without Arginine (A) with 10 or 100 µM
LY83583 in the presence of 1 nM BMP2 with and without 100 µM Deta NONOate. (B) ALP activity
normalized to cell number after stimulation for 72 h in DMEM/Hams with 10 nM BMP2 and sGC
inhibitor LY83583 (0.01 to 0.5 µM). Statistics: Kruskal–Wallis Test followed by Mann-Whitney U test.
Mann-Whitney U test significances between samples were assigned if p < 0.05 (*) or p < 0.01 (**).
Abbreviation: Deta = Deta NONOate. Stars and circles are outlying values. Replications (A) n = 9,
(B) n = 6.
To further investigate the direct connection between sGC and BMP2-mediated signaling,
the NO-independent activator YC-1 was applied to C2C12BRELuc cells in combination with 1 nM
BMP2 (Figure 8). The addition of 10 and 30 µM YC-1 alone significantly increased BMP reporter activity
(Figure 8A). A similar trend was seen when additional BMP2 was added to the cultures (Figure 8B).
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to BMP2 had no additional effect on the SMAD1 phosphorylation under the tested conditions (Figure 
9B). 
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cell line stimulated for 24 h i DMEM without Arginine with (A) 0.5-3 µM YC-1 and (B) i combination
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values. Replications (A, B) n = 9.
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3.4. SMAD Signaling after BMP and NO Stimulation
The addition of the BMP type-I receptor inhibitor LDN, which inhibits BMP-mediated SMAD
signaling, led to a decrease of BMP reporter activity, irrespective of the presence of the NOS substrate
L-Arginine (Figure 9A). Analyzing the phosphorylation of SMAD1, this effect could be underlined,
as the inhibitor LDN significantly reduced the SMAD1 phosphorylation. Arginine supplementation to
BMP2 had no additional effect on the SMAD1 phosphorylation under the tested conditions (Figure 9B).Cells 2019, 8, x 13 of 22 
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SMAD1. Statistics: Kruskal–Wallis Test followed by Mann-Whitney U test. Mann-Whitney U test 
significances between samples were assigned if p < 0.05 (*) or p < 0.01 (**). Abbreviations: LDN: LDN-
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3.5. PKA Connects BMP2 and NO Pathway for BMP2 Signaling 
A PKA-mediated link between the BMP2 and NO pathway has been described [27]. To 
investigate this connection, the PKA inhibitor H89 was used. Application of 1 μM H89 significantly 
reduced BMP2-induced signaling. The inhibition of BMP2 signaling was rescued by the application 
of 100 μM Deta NONOate (Figure 10). 
 
 
Figure 10. BMP reporter activity after inhibition of protein kinase A (PKA) by H89: BMP reporter 
activity of C2C12BRELuc cells stimulated for 6 h with 1 nM BMP2, 1 μM H89, 10 and 100 μM Deta 
NONOate. Statistics: Kruskal–Wallis Test followed by Mann-Whitney U test. Mann-Whitney U test 
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Figure 9. BMP reporter activity and SMAD1 phosphorylation after inhibition of the SMAD pathway.
(A) C2C12BRELuc cells were stimulated for 6 h in Arginine-free DMEM with 1 nM BMP2 with or without
1 mM Arginine and 0.5 µM LDN. (B) C2C12BRELuc cells were stimulated for 30 min in Arginine-free
DMEM with 1 nM BMP2 ith or without 1 m rgi ine a d 0.5 µM LDN. SMAD1 phosphorylation
was measured with the SMAD1 InstantOne ELISA™ kit and normalized to total SMAD1. Statistics:
Kruskal–Wallis Test followed by Mann-Whitney U test. Mann-Whitney U test significances between
samples were assigned if p < 0.05 (*) or p < 0.01 (**). Abbreviations: LDN: LDN-193189 (A) n = 6;
(B) n = 3.
3.5. PKA Connects BMP2 and NO Pathway for BMP2 Signaling
A PKA-mediated link between the BMP2 and NO pathway has been described [27]. To investigate
this connection, the PKA inhibitor H89 was used. Application of 1 µM H89 significantly reduced
BMP2-induced signaling. The inhibition of BMP2 signaling was rescued by the application of 100 µM
Deta NONOate (Figure 10).
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NONOate. Circles are outlying values. Replications n = 6.
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3.6. BMP2 Can Induce NO Pathway Activity
We hypothesized that BMP2 is able to activate the NO pathway. To prove this, NO and
cGMP production was examined in response to BMP2 (Figure 11). The quantification of NO was
carried out using the fluorescent NO reactive DAF-2. The addition of 10–50 nM BMP2 led to
a dose-dependent increase in NO production, but only 50 nM BMP2 was significantly higher compared
to the untreated group (Figure 11A) and comparable to the NO donor Deta NONOate. Stimulation
of cells with 5 nM BMP2 significantly increased the cGMP production compared to the untreated
group. The BMP2-induced cGMP production was comparable to the amount induced by 100 µM Deta
NONOate (Figure 11B).
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4. Discussion
This study aimed to investigate the molecular association between the BMP2 and NO pathways
and to gain further understanding of the ability of the NO pathway to enhance BMP2-mediated
signaling and osteoinductive activities. To this end, BMP2 was applied in combination with various
compounds that stimulate or inhibit the NO pathway in C2C12 cells, and BMP2 reporter activity
and osteoinduction (ALP activity) was measured. By demonstrating that the NO pathway can
enhance BMP2-mediated signaling and osteoinduction, there are opportunities to enhance BMP2-based
therapeutics, e.g., in fracture treatment, in turn filling the current need for increased BMP2 therapeutic
efficiency [45].
Utilizing Arginine-free DMEM as a cell culture medium allowed for better control of NO
signaling. Therefore, this study clearly demonstrated that NO production by the NOS enzyme
can enhance BMP2-mediated signaling. Supplementation of BMP2 stimulation with Arginine
enhanced BMP2-mediated reporter activity and the expression of BMP2 target genes Id1, Id2, and
Id3 after 6 h of stimulation. LNAME inhibition of the NOS enzyme confirmed the NO-BMP2 link.
However, high concentrations of LNAMEs were required (5 to 10 mM) to reduce BMP2-mediated
signaling. The reason could be the BMP2-mediated activation of the NOS enzyme [27] which, in turn,
acts as a competitor to the inhibition by LNAME.
The addition of the direct NO donors SNAP and Deta NONOate for a short period of time (6 h)
had no effect on BMP2-mediated signaling. However, SNAP addition without BMP2 was able to induce
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BMP reporter activity. At a longer period of time (24 h), Deta NONOate enhanced BMP2-mediated
signaling, whereas SNAP did not. This provides further evidence that the NO pathway can enhance
BMP2-mediated signaling. These time-dependent effects of direct NO donors are well-known due to
the variable half-life of the NO donors [46–48].
Investigating the phosphorylation of SMAD1, a clear effect of BMP2 was seen and the
phosphorylation was reduced by the BMP-receptor inhibitor LDN. As Arginine was not able to
recover the inhibition of the BMP2 pathway, NO supplementation might require a functional BMP
pathway. The reason for the ineffectiveness of Arginine on the additional stimulation of SMAD1
phosphorylation under BMP2 exposure cannot be explained, although a significant supplementary
effect on the reporter activity was detected. Further studies are necessary to elucidate if concentration
and time dependency might be responsible.
In this study, the supplementary role of the NO receptor sGC in BMP2-mediated signaling
was investigated using the chemical inhibitor LY83583 and the NO independent activator YC-1.
Application of the sGC inhibitor LY83583 reduced BMP2-mediated signaling, while addition of YC-1
had a supportive effect on the BMP2-mediated signaling. Taken together, these results demonstrate
a role for the NO receptor, sGC, in supporting BMP2-mediated signaling.
To understand if the NO pathway is able to support the early osteogenic differentiation in C2C12
cells, ALP activity and expression of osteogenic markers were investigated. As Arginine-free DMEM
did not allow the induction of ALP activity in C2C12 cells, a media containing Arginine was required
to investigate BMP2-mediated ALP activity. Therefore, Arginine supplementation could not be used,
and the role of NO in BMP2-mediated ALP induction was investigated by the application of direct
NO donors and NOS inhibitors. The application of NOS inhibitor (LNAME) in combination with
BMP2 inhibited the BMP2-mediated ALP activity, which was partially recovered by the addition
of the direct NO donor Deta NONOate. The osteogenic differentiation was further investigated by
gene expression analysis of the osteogenic markers OPG, Runx2, and Col1a1. The analysis revealed
that the NO substrate Arginine was able to enhance the osteogenic differentiation compared to
BMP2 alone. Altogether, this highlights the role of the NOS enzyme and NO pathway in supporting
BMP2-mediated early osteogenic activity, and that the addition of NO donors can help to enhance
BMP2-mediated activity.
There are dosing effects between BMP2 and Deta NONOate in the regulation of ALP activity.
This work demonstrated that the BMP2-mediated ALP activity of Deta NONOate was only achieved at
higher BMP2 concentrations (10 and 20 nM). In addition, while Deta NONOate was supplementary at
low concentrations (10 µM), it lost effectiveness and became inhibitory with increasing concentrations.
It is interesting to note a parallel effect seen in stretching experiments of C2C12 cells: 10 µM
Deta NONOate enhanced stretch induced proliferation, whereas 50 or 100 µM had no effect [49].
Therefore, further studies are needed to determine the NO donor concentration required to achieve
the most effective activity, as well as to elucidate the mechanism of adverse effects with increasing
NO concentration.
The negative effects of NO on cell vitality were previously described [50–53]. Particularly, in C2C12
cells, the NO donor SNP reduced the cell number and increased the apoptotic markers p53 and caspase-3
in a concentration- and time-dependent manner [54]. However, in differentiated C2C12 cells treated
with 0.35 to 3 mM Deta NONOate for 24 h, viability studies found that at the lowest concentration
(0.35 mM), cell viability was 82.1%, while at the highest concentration (3 mM), cell viability dropped
to 41.5% [55]. Over 24 h Deta NONOate was able to enhance stretch-induced proliferation of C2C12
at 10 µM, but this was lost at higher concentrations (50–100 µM) and did not reduce proliferation
compared to control [49]. In the C2C12BRELuc cells used in this study, the application of 10 to 100 µM
Deta NONOate had little to no negative effects on C2C12BRELuc viability over 24 h. A decrease in
p53, however, might also be associated with osteogenic differentiation as reported earlier for mouse
bone marrow-derived mesenchymal cells [56]. The authors found that p53 indirectly suppresses
Runx2 expression.
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In clinical use, a high concentration of BMP2 is applied, possibly contributing to the negative
side effects seen in patients [57,58]. The ability of Arginine, YC-1, and Deta NONOate to supplement
BMP2-mediated signaling and early osteogenic differentiation provides an opportunity to reduce
the amount of BMP2 applied in the clinic while maintaining the osteoinductive effects. As NO
pathway activators (such as nitroglycerine) have been previously used in clinical trials as an orthopedic
therapy [34,35,59,60], this should provide a valuable starting point for future investigations into
compounds that can be applied clinically in combination with BMP2.
Furthermore, it was noticed that Deta NONOate-, SNAP-, and YC-1-mediated activation of the NO
pathway led to a BMP2-independent activation of BMP reporter activity. This could be an indication
of an increase in BMP2 expression, as shown in cultured embryonic heart cells in response to NO
pathway activation [61], or though osteoinduction as seen in MC3T3 cells [62,63].
It was previously shown that PKA connects BMP2 signaling with the activation of eNOS through
phosphorylation in pulmonary cells [27]. This possible link was investigated now in a more osteogenic
context. The application of the PKA inhibitor H89 led to inhibition of BMP2-mediated signaling,
which was recovered by the addition of the direct NO donor, Deta NONOate. This underlines
a connection between BMP2, PKA, and the NO pathway. This finding is in agreement with results
reported in previous work, where it was shown that PKA activation itself leads to osteoinduction in
MC3T3 cells [64,65], also involving the PKA/CREB signaling [66].
This study showed the ability of the BMP2 pathway to activate the NO pathway through
an increase of NO and cGMP production in C2C12 cells. BMP2-stimulated NO production was
clearly dose-dependent, with NO production increasing with higher BMP2 concentrations. This is
in line with previous studies, where increasing BMP2 concentration increased the NO production
in chondrocytes [67]. In endothelial cells, BMP2 enhanced the NOS activity. However, the BMP2
dosage effects on NOS activity was not investigated [27]. This study required a high concentration
(50 nM) of BMP2 to significantly increase NO production compared to other studies [27,67], which was
partially due to the short stimulatory time required for DAF-2-mediated NO quantification (2 h)
compared to the longer times point of Griess assay (4 d) used for BMP2 treated chondrocytes [67].
The BMP2-mediated activation of the NO pathway also increased the cGMP level. This builds on
previous studies, which have focused on the association of the BMP2 signaling with the cGMP-activated
cGKI. It was demonstrated that the addition of 8-br-cGMP increased cGKI binding of the BMPR2 tail
domain [26], but previous studies have overlooked whether addition of BMP2 leads to an increase
in cGMP production. Collectively, this and previous work [26,27,67] suggest a possible positive
reinforcement of BMP2 signaling, whereby BMP2 is enhanced by the NO pathway and BMP2 itself can
activate the NO pathway.
This work provided evidence that the NO pathway is capable of enhancing BMP2-mediated
signaling and early osteogenic differentiation, which can have implications for the application of
BMP2 in the clinic. Further, it was demonstrated that PKA connects BMP2 and NO signaling.
This investigation has solidified the role of NO in activating the BMP2 pathway by demonstrating this
in the C2C12 cells. Further studies should investigate the effect on osteogenic differentiation in vitro
and in vivo by addressing the effect on mineralization in vitro and ectopic, as well as heterotopic bone
formation in vivo.
5. Conclusions
The presented data show that there is a crosstalk between the NO and BMP signaling pathway
and that NO leads to enhanced BMP activity (summarized in Figure 12). The NO pathway is linked to
the BMP pathway via sGC, with PKA mediating the link between BMP2 and NO pathway.
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